Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foretinib in Triple Negative Breast Cancer
NCT01147484Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Sep 2010
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of foretinib in triple-negative breast cancer (TNBC), sponsored by Canadian Cancer Trials Group. Started Sep 2010; status: completed.
02
Drugs
foretinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01147484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147484.